TONIX PHARMACEUTICALS HOLDIN (TNXP) Fundamental Analysis & Valuation

NASDAQ:TNXP • US8902608392

Current stock price

13.6 USD
+0.67 (+5.18%)
At close:
13.2 USD
-0.4 (-2.94%)
After Hours:

This TNXP fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. TNXP Profitability Analysis

1.1 Basic Checks

  • TNXP had negative earnings in the past year.
  • TNXP had a negative operating cash flow in the past year.
  • In the past 5 years TNXP always reported negative net income.
  • TNXP had a negative operating cash flow in each of the past 5 years.
TNXP Yearly Net Income VS EBIT VS OCF VS FCFTNXP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50M -100M

1.2 Ratios

  • TNXP has a Return On Assets (-44.75%) which is comparable to the rest of the industry.
  • TNXP's Return On Equity of -50.59% is fine compared to the rest of the industry. TNXP outperforms 60.78% of its industry peers.
Industry RankSector Rank
ROA -44.75%
ROE -50.59%
ROIC N/A
ROA(3y)-66.7%
ROA(5y)-58.04%
ROE(3y)-84.77%
ROE(5y)-70.59%
ROIC(3y)N/A
ROIC(5y)N/A
TNXP Yearly ROA, ROE, ROICTNXP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100 -200 -300

1.3 Margins

  • Looking at the Gross Margin, with a value of 49.34%, TNXP is in the better half of the industry, outperforming 74.17% of the companies in the same industry.
  • TNXP does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 49.34%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TNXP Yearly Profit, Operating, Gross MarginsTNXP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K -1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. TNXP Health Analysis

2.1 Basic Checks

  • TNXP does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, TNXP has more shares outstanding
  • Compared to 5 years ago, TNXP has more shares outstanding
  • TNXP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TNXP Yearly Shares OutstandingTNXP Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
TNXP Yearly Total Debt VS Total AssetsTNXP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

2.2 Solvency

  • TNXP has an Altman-Z score of -1.47. This is a bad value and indicates that TNXP is not financially healthy and even has some risk of bankruptcy.
  • TNXP has a Altman-Z score (-1.47) which is in line with its industry peers.
  • TNXP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.47
ROIC/WACCN/A
WACC9.44%
TNXP Yearly LT Debt VS Equity VS FCFTNXP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M

2.3 Liquidity

  • TNXP has a Current Ratio of 7.42. This indicates that TNXP is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 7.42, TNXP is in the better half of the industry, outperforming 68.74% of the companies in the same industry.
  • A Quick Ratio of 7.23 indicates that TNXP has no problem at all paying its short term obligations.
  • With a decent Quick ratio value of 7.23, TNXP is doing good in the industry, outperforming 67.96% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.42
Quick Ratio 7.23
TNXP Yearly Current Assets VS Current LiabilitesTNXP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. TNXP Growth Analysis

3.1 Past

  • TNXP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 99.44%, which is quite impressive.
  • The Revenue has grown by 29.85% in the past year. This is a very strong growth!
EPS 1Y (TTM)99.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.26%
Revenue 1Y (TTM)29.85%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%108.75%

3.2 Future

  • TNXP is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 28.88% yearly.
  • TNXP is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 172.61% yearly.
EPS Next Y33.78%
EPS Next 2Y31.74%
EPS Next 3Y28.88%
EPS Next 5YN/A
Revenue Next Year698.61%
Revenue Next 2Y232.33%
Revenue Next 3Y172.61%
Revenue Next 5YN/A

3.3 Evolution

TNXP Yearly Revenue VS EstimatesTNXP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 50M 100M 150M 200M
TNXP Yearly EPS VS EstimatesTNXP Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 -500M -1B -1.5B

More info and screens

Find the best growth stocksShow best growing peers

1

4. TNXP Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for TNXP. In the last year negative earnings were reported.
  • Also next year TNXP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TNXP Price Earnings VS Forward Price EarningsTNXP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TNXP Per share dataTNXP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10

4.3 Compensation for Growth

  • A more expensive valuation may be justified as TNXP's earnings are expected to grow with 28.88% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.74%
EPS Next 3Y28.88%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TNXP Dividend Analysis

5.1 Amount

  • TNXP does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TNXP Fundamentals: All Metrics, Ratios and Statistics

TONIX PHARMACEUTICALS HOLDIN

NASDAQ:TNXP (5/1/2026, 8:00:01 PM)

After market: 13.2 -0.4 (-2.94%)

13.6

+0.67 (+5.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry Strength55.9
Industry Growth13.04
Earnings (Last)03-12
Earnings (Next)05-11
Inst Owners28.61%
Inst Owner Change0.1%
Ins Owners0.14%
Ins Owner Change0%
Market Cap193.26M
Revenue(TTM)13.11M
Net Income(TTM)-124.02M
Analysts82.5
Price Target65.79 (383.75%)
Short Float %17.45%
Short Ratio6
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-10.25%
Min EPS beat(2)-22.32%
Max EPS beat(2)1.82%
EPS beat(4)2
Avg EPS beat(4)-6.1%
Min EPS beat(4)-22.32%
Max EPS beat(4)13.8%
EPS beat(8)5
Avg EPS beat(8)-32.16%
EPS beat(12)7
Avg EPS beat(12)-19.12%
EPS beat(16)10
Avg EPS beat(16)-9.21%
Revenue beat(2)2
Avg Revenue beat(2)43.66%
Min Revenue beat(2)4.05%
Max Revenue beat(2)83.27%
Revenue beat(4)2
Avg Revenue beat(4)15.3%
Min Revenue beat(4)-19.5%
Max Revenue beat(4)83.27%
Revenue beat(8)2
Avg Revenue beat(8)-6.36%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.76%
PT rev (3m)-2.76%
EPS NQ rev (1m)-11.46%
EPS NQ rev (3m)-10.38%
EPS NY rev (1m)-18.83%
EPS NY rev (3m)-25.29%
Revenue NQ rev (1m)11.2%
Revenue NQ rev (3m)-34.25%
Revenue NY rev (1m)-1.21%
Revenue NY rev (3m)-2.38%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 14.74
P/FCF N/A
P/OCF N/A
P/B 0.79
P/tB 0.79
EV/EBITDA N/A
EPS(TTM)-14.27
EYN/A
EPS(NY)-9.45
Fwd EYN/A
FCF(TTM)-7.26
FCFYN/A
OCF(TTM)-7.03
OCFYN/A
SpS0.92
BVpS17.25
TBVpS17.24
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -44.75%
ROE -50.59%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 49.34%
FCFM N/A
ROA(3y)-66.7%
ROA(5y)-58.04%
ROE(3y)-84.77%
ROE(5y)-70.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 175.01%
Cap/Sales 25.7%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.42
Quick Ratio 7.23
Altman-Z -1.47
F-Score5
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)120.84%
Cap/Depr(5y)14966.9%
Cap/Sales(3y)42.84%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)99.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.26%
EPS Next Y33.78%
EPS Next 2Y31.74%
EPS Next 3Y28.88%
EPS Next 5YN/A
Revenue 1Y (TTM)29.85%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%108.75%
Revenue Next Year698.61%
Revenue Next 2Y232.33%
Revenue Next 3Y172.61%
Revenue Next 5YN/A
EBIT growth 1Y-61.69%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-69.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-63.88%
OCF growth 3YN/A
OCF growth 5YN/A

TONIX PHARMACEUTICALS HOLDIN / TNXP Fundamental Analysis FAQ

What is the fundamental rating for TNXP stock?

ChartMill assigns a fundamental rating of 4 / 10 to TNXP.


What is the valuation status of TONIX PHARMACEUTICALS HOLDIN (TNXP) stock?

ChartMill assigns a valuation rating of 1 / 10 to TONIX PHARMACEUTICALS HOLDIN (TNXP). This can be considered as Overvalued.


Can you provide the profitability details for TONIX PHARMACEUTICALS HOLDIN?

TONIX PHARMACEUTICALS HOLDIN (TNXP) has a profitability rating of 1 / 10.


What is the financial health of TONIX PHARMACEUTICALS HOLDIN (TNXP) stock?

The financial health rating of TONIX PHARMACEUTICALS HOLDIN (TNXP) is 7 / 10.